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ABSTRACT
Trans-splicing is a powerful approach to reprogram
the genome. It can be used to replace 50,3 0 or
internal exons. The latter approach has been
characterized by low efficiency, as the requirements
to promote internal trans-splicing are largely
uncharacterized. The trans-splicing process is
induced by engineered ‘RNA trans-splicing mol-
ecules’ (RTMs), which target a selected pre-mRNA
to be reprogrammed via two complementary
binding domains. To facilitate the development of
more efficient RTMs for therapeutic applications
we constructed a novel fluorescence based
screening system. We incorporated exon 52 of the
COL17A1 gene into a GFP-based cassette system
as the target exon. This exon is mutated in many
patients with the devastating skin blistering
disease epidermolysis bullosa. In a double transfec-
tion assay we were able to rapidly identify optimal
binding domains targeted to sequences in the sur-
rounding introns 51 and 52. The ability to replace
exon 52 was then evaluated in a more endogenous
context using a target containing COL17A1 exon 51–
intron 51–exon 52–intron 52–exon 53. Two selected
RTMs produced significantly higher levels of GFP
expression in up to 61% assayed cells. This novel
approach allows for rapid identification of efficient
RTMs for internal exon replacement.
INTRODUCTION
Conventional gene therapy strategies are designed to
deliver the full-length cDNA copy of a therapeutic gene
to produce a functional protein. However, these
approaches have disadvantages that may reduce the
chance of therapeutic success, including the difﬁculty to
package and deliver large genes and the lack of endogen-
ous regulation of the transgene expression in target cells.
Moreover, autosomal dominant disorders may not be
amenable to treatment by these conventional therapeutic
approaches. These problems can be overcome by using a
gene correction strategy, such as spliceosome mediated
RNA trans-splicing. This pre-mRNA based method is
characterized by the exploitation of naturally occurring
splicing events during mRNA maturation (1,2). The en-
dogenous splicing machinery is utilized to recombine two
independent RNA molecules by trans-splicing, replacing
the disease causing part of a gene by a wild-type version in
an exon-wise manner. The trans-splicing process is
directed by engineered ‘RNA trans-splicing molecules’
(RTMs), which base-pair with a region of a target
pre-mRNA via a complementary binding domain (BD).
This interaction between the RTM and the target
pre-mRNA confers speciﬁcity. Besides the BD, RTMs
contain two other elements: a 50 and/or a 30 splice site
that promote the trans-splicing reaction, and a wild-type
coding region that can replace that region with any
sequence ranging from a single exon to one or more
genes, thus repairing the target gene or reprogramming
it to encode any gene of interest.
An RTM can be designed to replace 30,5 0 or internal
sequences of a target pre-mRNA to generate a new gene
product (1). After binding to the target pre-mRNA, the
trans-splicing process is initiated by the RTM, of which
the splicing and coding domains provide recognition se-
quences for the spliceosome to facilitate what is essentially
an alternative splicing reaction in trans. The efﬁciency of
the trans-splicing process depends on the BD and the
strength of the splice site sequences of the RTM (3,4).
There is a wide range of factors that inﬂuence the
decision to splice (5). These factors remain largely unex-
plored in the context of RNA trans-splicing.
*To whom correspondence should be addressed. Tel: +43 662 44823118; Fax: +43 662 44823125; Email: u.koller@salk.at
Published online 17 June 2011 Nucleic Acids Research, 2011, Vol. 39, No. 16 e108
doi:10.1093/nar/gkr465
 The Author(s) 2011. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Most reports on RNA trans-splicing for gene correction
have employed 30 exon replacement to exchange down-
stream coding sequences of a gene of interest. 30 trans-
splicing therapy approaches have been successful in
restoring potentially therapeutic levels of gene function
in patient cells and in animal models of cystic ﬁbrosis,
X-linked immunodeﬁciency and hemophilia A (6–9).
For correction of the upstream regions of a gene, 50
trans-splicing was ﬁrst reported using a double transfec-
tion model to correct mutations expressed by a
plasmid-encoded cystic ﬁbrosis transmembrane receptor
(CFTR) pre-mRNA. Those RTMs were designed to
replace the 50 portion of a transcript, inserting the 1.9kb
sequence coding for exon 1–10 of the CFTR gene (3).
Similarly, 50 trans-splicing has been used to replace
b-globin exon 1 in cells co-transfected with target and
RTM expressing plasmids (10). Endogenous 50 trans-
splicing correction was ﬁrst reported in 2008 by Wally
et al., (11) who demonstrated that an RTM can correct
over 1kb of the upstream coding region of the PLEC
gene. Restoration of normal plectin expression patterns
were detected by immunoﬂuorescence microscopy after
RTM transfection of epidermolysis bullosa (EB) patient
ﬁbroblasts. Additionally, Wally et al. developed a 50 trans-
splicing strategy to speciﬁcally reprogram exons 1–7 of the
keratin 14 gene (KRT14) in an autosomal dominant model
of EB-simplex, leading to a phenotypic reversion of RTM
treated cells in vitro (12).
RNA trans-splicing can also be used for internal exon
replacement (IER) to correct internal coding regions of a
gene by using the combination of 50 and 30 trans-splicing
(1,13,14). Here, an RTM with two BDs base-pairs up and
downstream of the region to be replaced (i.e. a mutated
exon), inducing the trans-splicing of a wild-type exon from
the RTM to the naturally ﬂanking exons of the endogen-
ous target pre-mRNA. The main advantage of this
method is the possibility to manufacture and deliver an
RTM with a relatively short sequence into patient cells,
thereby minimizing the size of the construct and many
size-associated limitations.
As a prototypic gene to perform IER, we analyzed the
collagen 17A1 (COL17A1) gene, which is mutated in the
non-Herlitz junctional form of EB (15). EB is a genetically
and clinically heterogeneous group of skin diseases
characterized by blister formation and erosions of the
skin and mucous membranes after minor trauma.
To date, more than 10 different genes that encode for
structural proteins within keratinocytes or mucocutaneous
basement membranes have been linked to EB. The severity
of the disease depends on which gene is mutated and the
localization of the mutation within this gene (16,17).
Here, we constructed a novel RTM screening system, in
which the reporter molecule acGFP acts as marker for
speciﬁc double trans-splicing events in the COL17A1
gene in vitro. The acGFP gene was split into three parts.
The middle (internal) part was cloned into an RTM
capable of performing two targeted trans-splicing reac-
tions. The 50 and 30 parts of GFP were cloned into the
target molecule ﬂanking the genomic target sequence of
COL17A1 intron 51–exon 52–intron 52. We show that this
screening system can be used to rapidly identify those
RTMs, which produce the highest levels of trans-splicing
and function.
MATERIAL AND METHODS
Cell culture and transfection
The human embryonic kidney cell line HEK293AD
(Stratagene) was utilized for screening experiments. Cells
were grown at 37 C and 5% CO2 in a humidiﬁed incuba-
tor in DMEM supplemented with 10% FCS and 100U/ml
penicillin/streptomycin (Biochrom). Passaging of the cells
was performed every 4–5 days using 1% Trypsin–EDTA
(Biochrom), and cells were pelleted by centrifugation at
170g for 5min. Afterwards cells were seeded to a new
tissue culture plate at the desired density. Cells were tran-
siently transfected using jetPEI (Polyplus-transfection SA,
Illkirch, France). Various amounts of plasmid DNA
(1–10mg) were applied according to the manufacturer’s
protocol.
Target molecule construction
The engineered target molecule consists of a short 50
region of acGFP sequence (183bp), a COL17A1 target
region consisting of intron 51, exon 52, intron 52 and
the 30-coding region of acGFP (231bp). The target was
constructed by PCR ampliﬁcation of the acGFP split
parts (50 acGFP forward primer: 50-gatcggatcccaccatggt
gagcaagggcgcc-30,5 0acGFP reverse primer: 50-tatgatatcac
actcaccagggtgggccagggcac-30,3 0acGFP forward primer:
50-gatcgcggccgcttttccctccaggtgaacttcaagatccgc-30,3 0
acGFP reverse primer: 50-gatctctagatcacttgtacagctcatcc-30)
and the target region intron 51–exon 52–intron 52
COL17A1 (intron 51 COL17A1 forward primer: 50-tatg
atatcggtgccccgacggtgatgccccacc-30, intron 52 COL17A1
reverse primer: 50-gatcgcggccgcgtaaaacaccagagcttgggcaca
gg-30) using Pfu Turbo DNA polymerase (Stratagene).
The pacGFP vector (Clontech) and genomic DNA from
a healthy donor was used as PCR template, respectively.
The 50 acGFP region was cloned into the expression vector
pcDNA 3.1D/V5-HIS (Invitrogen), using the restriction
enzymes BamHI and EcoRV. A 50 splice site (ag/
gtgagtgt) was included in the reverse ampliﬁcation
primer and cloned at the junction between the 50 acGFP
region and intron 51 of COL17A1. The restriction
enzymes EcoRV and NotI were used for cloning of the
wild-type sequence of intron 51–exon 52–intron 52 of
COL17A1, followed by a 30 splice site (gcggccgcttttccctcc
ag/g) and the 30 fragment of acGFP, which was cloned
using NotI and XbaI sites. Plasmid preparations were
carried out using the Plasmid Mini Prep Kit from
Sigma-Aldrich (St. Louis, MO, USA), according to the
manufacturer’s protocol. All constructs and PCR
products were sequenced using a 3130 ABI Prism auto-
mated sequencer and ABI PRISM dye terminator cycle
sequencing kits (Applied Biosystems, Foster City, CA,
USA). PCR products were gel extracted before sequence
analysis using the GFX
TM PCR DNA and Gel Band
Puriﬁcation Kit (GE Healthcare).
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The COL17A1 mini-gene target plasmid was constructed
by cloning a PCR ampliﬁed product containing the
COL17A1 target region exon 51–intron 51–exon
52–intron 52–exon 53 into the vector pcDNA 3.1D/
V5-HIS (Invitrogen). PCR was performed using an exon
51 COL17A1 speciﬁc forward primer (50-gatcggatccc
tgccggcttgtcattcatcccaggcc-30) and an exon 53 COL17A1
speciﬁc reverse primer (50-gatctctagatttggaagaagtccatgagg
tccgcagtcacgtt-30), Pfu Turbo DNA polymerase
(Stratagene) and genomic DNA from an EB patient with
a homozygous mutation (3898 del TC) in the COL17A1
gene. The resulting PCR product was cloned into the ex-
pression vector using the restriction sites for BamHI and
XbaI.
Sequential construction to produce a double
trans-splicing RTM
Selection of an initial 50 BD. A5 0 BD targeting the region
of COL17A1 exon 52/intron 52 was selected for the ﬁrst
step in construction of a double trans-splicing RTM using
a split GFP reporter model system according to the
method of Wally et al. (12). In brief, the constructs were
produced using the split reporter acGFP instead of
dsRED. A 50 BD library was constructed and  40
randomly picked clones were sequenced. Seventeen
RTMs with BDs ranging from 78 to 314nt that were com-
plementary to essentially all regions of the exon 52–intron
52 target were identiﬁed and tested for trans-splicing efﬁ-
ciency by quantifying GFP expression using ﬂow
cytometry. The most efﬁcient BD was PCR ampliﬁed
with primers containing ﬂanking NotI sites.
Initial double trans-splicing RTM construction. The double
trans-splicing RTM screening cassette vector was created
in three steps. First, a pIRES2-AcGFP1 vector (Clontech)
was digested with EcoRI and KpnI. Elements of the 30
trans-splicing arm were introduced as double stranded
synthesized oligos into these sites, including an EcoRV
site for later cloning in a BD library, a spacer and a
branch point (underlined) (50-gaattcgttaacgatatcgagaacatt
attatagcgttgctcgagtactaactggtacc-30). Second, the internal
portion of acGFP (306bp) was generated by PCR using
Pfu Turbo DNA polymerase (Stratagene).
The forward primer (50-tatggtacctcttcttttttttctgcaggtga
ccaccctgagctac-30) contains a KpnI site and the remainders
of the 30 splice site to generate a functional 30 RTM con-
taining the same elements as previously described (18).
The reverse primer (50-tatgcggccgctgtaataatatcgcaacgagct
ctcttaccttgatgccattcttggcc-30) contains a 50 splice site, a
spacer region and a NotI restriction site. These two
cloning steps removed the IRES and full-length GFP se-
quences from the Clontech vector. Finally, the selected
50 BD was cloned into the NotI restriction site. The result-
ing clones were sequenced to select one with the correct
(complementary) orientation.
Selection of a 30 binding domain. A3 0 BD library was con-
structed by fragmenting the PCR ampliﬁed target
sequence of COL17A1 intron 51/exon 52 using CviJI*
(Roboklon; Berlin, Germany).
Partial CviJI* digestion of this 676bp region was per-
formed for 1–10s at 37 C and the resulting fragments
were pooled. CviJI* cleaves and produces blunt end
DNA fragments between the G and C at the sequence
50-PuGCPy-30. The resulting fragments were cloned
upstream of the 30 RTM spacer region into the EcoRV
site. After cloning, 90 individual bacterial clones were
checked for the presence of a BD fragment by colony
PCR. DNA sequencing showed that  95% of clones con-
tained at least one BD,  50% were complementary to the
target region. Fifty-four RTMs harboring one or more
complementary BDs were tested for trans-splicing efﬁ-
ciency quantifying GFP expression by ﬂow cytometry.
Geometric mean calculations were performed using the
program FlowJo (Treestar). The most efﬁcient BD target-
ing intron 51 was chosen for further development.
Selection of improved 50 BD. To improve the RTM
selected above, an additional round of 50 BD screening
was performed. An EcoRV restriction site was introduced
at the 50 RTM spacer sequence downstream of the internal
acGFP fragment by performing a second PCR ampliﬁca-
tion of the acGFP fragment using an internal acGFP
forward primer (50-tatggtacctcttcttttttttctgcaggtgaccacc
ctgagctac-30) and an internal acGFP reverse primer
(50-gatcgcggccgcgatatcttaataatatcgcaacgagctctcttaccttgatg
ccattcttggcc-30). The resulting PCR product was subse-
quently cloned into the RTM vector using the restriction
enzymes KpnI and NotI. The PCR ampliﬁed COL17A1
target region exon 52/intron 52 was CviJI* digested as
previously described and the resulting DNA fragments
were cloned into the EcoRV site. Twenty-seven RTMs,
harboring one or more complementary BDs for the
target region were tested for trans-splicing efﬁciency by
quantifying GFP expression using ﬂow cytometry. Two
low efﬁciency RTMs (RTM 1 and 3) and the two RTMs
with the highest trans-splicing efﬁciency (RTM 2 and 4)
were selected for further experiments.
RNA isolation and cDNA synthesis
RNA was isolated from 10
6 cells using the RNeasy Mini
Kit (Qiagen) according to the manufacturer’s protocol.
Puriﬁed RNA (1–2mg) was digested with DNase I
(Sigma) for 30min at RT, which was subsequently
inactivated by incubation for 10min at 70 C, followed
by cDNA synthesis using the iScript
TMcDNA Synthesis
Kit (Biorad) with the provided mixture of oligo(dT) and
random hexamer primers for cDNA synthesis.
RT–PCR
Exon replacement was detected by RT–PCR using GoTaq
polymerase (Promega) and the following conditions: 95 C
for 5min, 50 cycles of 30s at 95 C, 30s at 65 C, 30s at
72 C, and a ﬁnal extension of 7min at 72 C, speciﬁc
primers for acGFP (50 acGFP speciﬁc forward primer:
50-gatcggatcccaccatggtgagcaagggcgcc-30 and 30acGFP
speciﬁc reverse primer: 50-cgccgatgggggtattctgctgg-30) and
cDNA. Expected PCR products were the trans-splicing
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52–30acGFP, and the fusion mRNA 50acGFP–30acGFP
created by exon skipping on the target molecule.
Co-transfection of single RTMs and the COL17A1
mini-gene target plasmid into HEK293AD cells
produced two distinct splicing products, a trans-spliced
product (exon 51–middle portion of acGFP–exon 53)
and a cis-spliced product (exon 51–exon 52–exon 53).
These mRNAs were ampliﬁed by RT–PCR in one
reaction using the COL17A1 mini-gene speciﬁc primer
pair (exon 51 COL17A1 speciﬁc forward primer: 50-ggag
cgagctgatcagctacctcac-30, and exon 53 COL17A1 speciﬁc
reverse primer: 50-gccatcccttgcagtaggccctg-30) and the
same conditions as described above.
Flow cytometry
Fluorescence microscopy and ﬂow cytometric analysis was
performed 2–4 days after RTM and target plasmids were
co-transfected into HEK293AD cells. For cytometry, the
transfected HEK293AD cells were washed with PBS
buffer (Dulbecco’s PBS), trypsinised to release the cells
from the culture plates, and centrifuged for 5min at
170g. The cell pellet was resuspended in 500–1000ml
PBS and applied to the Beckman Coulter FC500.
Approximately 25000–80000 HEK293AD cells were
analyzed for GFP reporter gene expression. The CXP
software was used for data analysis.
FACS sorting and western blot analysis
Two days after HEK293AD cells were co-transfected with
RTM and target expression plasmids, acGFP protein ex-
pression was quantiﬁed by western blot analysis. Western
blot analysis was performed using either total cell extracts
from transfected HEK293AD cells or FACS selected GFP
positive cells (Beckman Coulter Epics Altra). Cells were
resuspended in lysis buffer (0.5M Tris–HCl, pH 6.8, 20%
Glycin, 10% SDS, 5% ß-Mercaptoethanol) containing a
protease inhibitor cocktail (Roche, Mannheim, Germany).
After addition of 4  loading buffer and denaturation at
95 C for 5min, SDS-gel-electrophoresis was performed at
100–150V for 1.5h using a NuPAGE 10% or 4–12% Bis–
Tris Gel (1.0mm 12 well) and a NuPAGE MOPS SDS
running buffer (20 ) (Invitrogen). Post-electrophoresis,
the SDS gel was equilibrated in standard blotting buffer
for up to 30min at RT, and then the proteins were electro-
blotted onto a nitrocellulose membrane (Amersham
Hybon-ECL, GE Healthcare) for 75min at 0.4 Ampere.
After the protein transfer, the membrane was soaked in
standard blocking buffer containing 1% western blocking
reagent (Roche) for 1h at RT. First antibodies, anti-GFP
rabbit IgG (Biomedica) and anti-Annexin I mouse mono-
clonal IgG (Santa Cruz Biotechnology), were diluted
1:1000 and 1:250 in TBS-T, respectively, containing
0.5% western blocking reagent and incubated with the
membrane over night at 4–8 C. The membrane was
washed with TBS-T, then incubated with HRP labeled
Envision
+ anti-rabbit antibody (diluted 1:50–1:100,
Dako) and HRP labeled Envision
+ anti-mouse antibody
(diluted 1:250–1:500, Dako) in TBS-T containing 0.5%
Western blocking reagent. After washing with TBS-T the
blot was visualized using the Immun-Star WesternC Kit
(Biorad). Protein quantiﬁcation was performed using the
program Image Lab 3.0.1. (Biorad).
RESULTS
Rational design, construction and evaluation of
RTM-BDs can be an arduous and time consuming
process as the requirements for single or double trans-
splicing are essentially unknown. To facilitate this
process, a rapid method to identify the most efﬁcient
trans-splicing RTMs is desirable. We have developed a
screening system that can be used to select the most efﬁ-
cient double trans-splicing RTMs from a library contain-
ing numerous RTMs with different BDs that are
complementary to the target region.
Selection of an initial 50 BD
To begin, we decided to identify a working 50 BD targeting
COL17A1 exon 52 / intron 52 using the screening system
previously published by Wally et al. (12). To minimize the
complexity of screening and selecting for two BDs simul-
taneously, we chose to proceed in a sequential manner,
selecting one BD at a time. Seventeen RTMs speciﬁc for
exon/intron 52 were individually tested for trans-splicing
induced restoration of GFP expression by ﬂow cytometry
(data not shown). The BD of the 50 RTM that generated
the highest level of GFP expression was incorporated into
the 50 trans-splicing arm of a double trans-splicing RTM
vector (version 1).
Screening for double trans-splicing efﬁciency
Since 30 and 50 trans-splicing have to work in synchrony,
we feel that screening for the most efﬁcient BDs for double
trans-splicing should be done in the context of a double
trans-splicing RTM. Our double trans-splicing ﬂuores-
cence based screening system utilizes two pre-mRNA com-
ponents, a target molecule containing a disease associated
region of the COL17A1 gene and a library of RTMs that
can potentially trans-splice and restore the coding
sequence of a reporter gene ﬂanking the target sequence
(Figure 1). Trans-splicing efﬁciency can be evaluated by
restoration of reporter gene expression. For this screen,
the reporter acGFP was divided into three portions and
strategically cloned into the target molecule and the RTM.
The 50 and 30 parts of acGFP were cloned into the target
vector ﬂanking the COL17A1 intron 51–exon 52–intron 52
target region. The double trans-splicing RTMs carry the
middle portion of acGFP ﬂanked by a 30 a n da5 0 trans-
splicing arm, each consisting of a BD and a 50 or 30 splice
site. A diversity of RTMs, differing in their target speciﬁc
BD sequences was created by fragmenting the target
region of COL17A1 and blunt end cloning of the resulting
fragments into the RTM vector.
Screening for an efﬁcient 30 BD
A random 30 BD library targeting COL17A1 intron
51–exon 52 was constructed as described in the methods
section and cloned into the double trans-splicing
RTM vector (version 1) harboring the initial working
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pendent RTMs, 90 unique RTMs were sequenced and 54
with complementary BDs were identiﬁed. Each of these
RTMs was individually tested by co-transfection with
target plasmid into HEK293AD cells and analyzed for
trans-splicing efﬁciency by GFP expression using ﬂow
cytometry. After calculating the average GFP expression
of RTM treated cells, the 30 BD of the most efﬁcient RTM
was chosen for further RTM improvement.
Screening for an efﬁcient 50 BD
The main aim of this additional screen was the further
improvement of the existing RTM by screening for
a new 50 BD that works well together with the
selected 30 BD speciﬁc for intron 51 and better than the
initial 50 BD speciﬁc for exon/intron 52 (Figure 2B).
Twenty-seven different RTMs, with the selected 30 BD
(Figure 3) and a variable BD for 50 trans-splicing, were
evaluated for efﬁcient trans-splicing efﬁciency by ﬂow
cytometry. The geometric mean of GFP expression in
RTM treated cells ranged from 2.6 to 3.5. Geometric
mean calculation was performed only for RTMs that
induced GFP expression in >5% of all analyzed cells.
Five RTMs (RTM 0, 1, 2, 3, 4) from the 50 double
trans-splicing RTM library were selected as candidates
for further experiments shown in this study (Figure 3).
RTM 0 lacks a BD for the 50 trans-splicing reaction and
was therefore included as negative control in the experi-
ment. RTMs 1 and 3 were representatives for less func-
tional RTMs, as the level of acGFP expression was
decreased in comparison to the most efﬁcient RTMs 2
and 4.
Exon replacement on mRNA level
A COL17A1 speciﬁc double trans-splicing RTM is able to
recombine with a target pre-mRNA by two synchronous
trans-splicing reactions (50 and 30). Thus the exon on the
target molecule should be replaced by the middle portion
of acGFP, restoring the open reading frame of acGFP
A
Target Molecule
5‘ acGFP
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5‘SS 3‘SS Exon 52 3‘ acGFP
Intron 52
5‘SS 3‘SS
BP pPT
3‘SS int. acGFP 5‘SS
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D B ‘ 5 D B ‘ 3
Figure 1. Schematic description of the ﬂuorescence based RTM screening system. (A) The ﬂuorescence based RTM screen utilizes cells expressing
both an exon speciﬁc target molecule and an RTM. Trans-splicing induced RNA recombination between the target and the RTM pre-mRNAs
creates the fusion of all three acGFP fragments, thus restoring the full coding sequence and expression of functional acGFP. The target molecule
contains exon 52 and the ﬂanking introns of COL17A1, along with 50 and 30 fragments of acGFP. The RTM contains the internal coding region of
acGFP (the missing coding sequence) ﬂanked by a 30 and 50 splice site and other features required for the double-trans-splicing reaction. Each RTM
has two arms, containing an acceptor (30) or donor (50) splice site, a short spacer region and a ‘random’ BD created by fragmenting the COL17A1
target region. The randomized fragments were blunt ended, and cloned into the RTM backbone using the restriction site for EcoRV. (B) AcGFP
expression was visualized by ﬂuorescence microscopy in HEK293AD cells co-transfected with RTM and target molecule plasmids (40  magniﬁca-
tion). BP: Branch Point, pPT: Polypyrimidine Tract, SS: Splice Site, nt: nucleotides.
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treated cells.
One day after transfecting double trans-splicing RTMs
into HEK293AD cells, different splicing patterns were
observed by RT–PCR. Cis-splicing within the target
molecule generated an mRNA consisting of the 50 and 30
acGFP with exon 52 of COL17A1 in the middle. This
demonstrates that the acceptor (30) and donor (50) splice
sites at the exon / intron junctions were recognized by the
endogenous splicing machinery and that the target introns
were excised. The cis-spliced 50 acGFP–COL17A1 exon
52–30 acGFP fusion product was detected by RT–PCR
ampliﬁcation and agarose gel electrophoresis. This band
was visible in all HEK293AD cells transfected with target
plasmid (Figure 4, lanes 1, 4 and 5). Double trans-splicing
between the RTM and target molecule pre-mRNAs lead
to the replacement of exon 52 of the target molecule by the
internal acGFP sequence carried by the RTM. The result-
ing full-length GFP mRNA was exclusively detected in
HEK293AD cells co-transfected with both target and
RTM expression plasmids (Figure 4, lanes 4 and 5).
Since the products created by cis-o rtrans-splicing differ
in size, discrimination by RT–PCR is possible, as shown in
Figure 4, lanes 4 and 5, indicated bands. Skipping of exon
52 was also detected in cells transfected with the target
plasmid (Figure 4, lanes 1, 4 and 5). PCR products were
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Figure 2. Sequential construction of a double trans-splicing RTM. Since 30 and 50 trans-splicing have to work in synchrony, we believe that
screening for the most efﬁcient BDs for double trans-splicing should be done in the context of a double trans-splicing RTM. A random 30 BD
library targeting COL17A1 intron 51–exon 52 was constructed and cloned into the double trans-splicing RTM vector (version 1) harboring the initial
working 50 BD identiﬁed using the method of Wally et al. (A). To further improve the efﬁciency of the double trans-splicing RTM (version 2), a new
50 BD screen was performed using the efﬁcient 30 BD identiﬁed in the 30 BD screen (A) and a variable 50 BD speciﬁc for the COL17A1 exon/intron
52 target region (B).
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by DNA sequence analysis. The PCR primers used were
designed to hybridize to the 50 and 30 terminal regions of
the target molecule. No trans-spliced products were
detected in HEK293AD cells transfected exclusively with
RTM (Figure 4, lanes 2 and 3).
Double trans-splicing into the COL17A1 gene was
modeled using a mini-gene target plasmid that was con-
structed to express the endogenous pre-mRNA region
from exon 51 through exon 53. Successful double trans-
splicing should cause the replacement of COL17A1 exon
52 with the internal portion of acGFP (Figure 5A).
HEK293AD cells were co-transfected with plasmids ex-
pressing the COL17A1 mini-gene target and a single
RTM (1–4). Trans-splicing efﬁciency was evaluated by
RT–PCR using RNA extracted from these cells one day
post transfection. Trans-splicing between the target exons
and the middle portion of acGFP demonstrates the efﬁ-
ciency of the RTMs tested in the context of the endogen-
ous COL17A1 sequence (Figure 5B). Both splice products
(cis and trans) were ampliﬁed by RT–PCR and visualized
by agarose gel electrophoresis. These PCR products were
gel puriﬁed and conﬁrmed by DNA sequence analysis.
Flow cytometric analysis of treated HEK293AD cells
To detect acGFP repair and expression at the protein
level, ﬂuorescence microscopy and ﬂow cytometry were
performed on HEK293AD cells co-transfected with
RTM and target plasmids.
Two or more days post co-transfection with RTM and
target molecule the cells were evaluated for acGFP expres-
sion by ﬂuorescence microscopy. The fraction of acGFP
expressing cells and the expression level of GFP reporter
was also quantiﬁed by ﬂow cytometry. The sequences
700bp
600bp
500bp
400bp
5‘ acGFP int.  acGFP int. acGFP 3‘ acGFP
300bp
1 2           3            4            5            6            7
//
//
5‘ acGFP – Exon 52 – 3‘ acGFP (669bp) 
acGFP fusion (585bp) 
5‘ acGFP – 3‘ acGFP (279bp) 
target RTM2    RTM4    RTM2     RTM4     H2O
target target
Figure 4. Detection of acGFP restoration by double RNA trans-splicing on mRNA level. Trans-splicing on mRNA level can be detected by
RT–PCR in HEK293AD cells co-transfected with RTM 4 or RTM 2 and target molecule expressing plasmids. COL17A1 exon 52 replacement
by the internal acGFP fragment contributed by the RTM was detected using a 50 acGFP and 30 acGFP speciﬁc primer pair to discriminate between
cis- and trans-splicing events. The cDNA templates included: lane 1: target molecule alone, lane 2: RTM 2 plasmid only, lane 3: RTM 4 plasmid
only, lane 4: target molecule+RTM 2 plasmids, lane 5: target molecule+RTM 4 plasmids, lane 6: water control. The cis-splicing product 50acGFP -
exon 52 - 30acGFP (lanes 1, 4, 5), the trans-splicing product acGFP (lanes 4 and 5; The marked band in lane 4, indicated by an arrow, was sequenced
after recovery and gel extraction) or the exon skipping product 50 acGFP - 30 acGFP (lanes 1, 4, 5) was visualized on a 2% agarose gel after gel
electrophoresis. Lane 7: DNA ladder mix (Fermentas).
Intron 51 Intron 52 Exon 52
RTM 0
RTM 1
RTM 2
RTM 3
RTM 4
a
a
a
a
a
b
d
c
e
fg
Figure 3. 30 and 50 BDs of selected RTMs. The BD sequences have a
great inﬂuence on the efﬁciency of trans-splicing. Five RTMs selected
from an RTM library with the same 30 BD for intron 51 (a; binding
position from nt 106 of intron 51 to nt 257 of intron 51) of COL17A1
but with different BDs for the exon 52—intron 52 target region were
selected for further testing. RTM 0 had no 50-BD, whereas RTM 2 and
4 harbored two separate BDs speciﬁc for exon 52—intron 52. One
region of complementarity of RTM 2 masks the exon/intron
boundary of exon 52—intron 52 (c; binding position from nt 360 of
exon 52 to nt 190 of intron 52). The second domain repeats some of
same region of the 50-end of intron 52 (d; binding position from nt 20
to nt 63 of intron 52). RTM 4 binds to the central (f; binding position
from nt 318 to nt 338 of intron 52) and 30 (g; binding position from nt
457 to nt 555 of intron 52) portion of intron 52. RTMs 1 and 3 each
have one 50 BD complementary to the central portion of intron 52 (b;
nt 217 to nt 297 of intron 52, e; nt 191 to nt 297 of intron 52).
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of double trans-splicing RTMs as quantiﬁed by the
number of GFP positive cells and the level of GFP
produced. Compared with the less efﬁcient RTMs 1
(4.2% GFP positive cells) and 3 (12.8%), RTMs 2 and 4
produced signiﬁcantly higher levels of acGFP expression
in up to 61% of transfected HEK293AD cells (Figure 6G).
Background expression levels were less than 1% as
detected in cells co-transfected with target and RTM ex-
pression plasmid 0, which had no 50 BD (Figure 6D). No
acGFP expression was detected after single transfection
with target molecule, RTM 2, or RTM 4 (Figure 6A–C).
The geometric mean of RTM 1 and 3 was 2.17 and 2.53.
The most efﬁcient RTMs 2 and 4 had signiﬁcantly higher
values (geometric mean: 6.77 and 5.28) for the average
GFP expression.
Detection of acGFP by western blot analysis
Western Blot analysis was performed to demonstrate that
the portion of acGFP carried by the RTM trans-spliced
twice into target pre-mRNA in treated cells and correctly
assembled all three of the split parts of acGFP. The
repaired acGFP should be detected at the same position
as a full-length acGFP after immunostaining.
Western blot analysis was performed at least two days
after transfection using total cell extracts from transfected
HEK293AD cells to quantify the restoration of full-length
acGFP (27kDa) by trans-splicing (Figure 7). A full-length
acGFP-expressing plasmid was used as positive control in
the experiment (Figure 7, lane 2). AcGFP was visualized
after blotting and immuno-staining of HEK293AD total
protein extracts from cells co-transfected with target
molecule along with either RTM 2, 3, or 4 (Figure 7,
lanes 4, 6 and 7). RTMs 0 and 1 were not able to
generate a detectable acGFP band (Figure 7, lanes 5, 8).
These RTMs also produced less than  5% GFP positive
cells as quantiﬁed by ﬂow cytometric analysis. No acGFP
expression was detected after single transfection of target
molecule, RTM 4 or RTM 2 alone into HEK293AD cells
(Figure 7, lanes 9–11). HEK293AD cells co-transfected
A
COL17A1 mini-gene
Exon 51
Intron 51
5‘SS 3‘SS Exon 52
Intron 52
5‘SS 3‘SS
BP      pPT
3‘SS int. acGFP
5‘SS
r e c a p S r e c a p S RTM
Exon 51 int. acGFP Exon 53
3‘ trans ‘ 5 g n i c i l p s - trans-splicing
COL17A1- acGFP fusion mRNA
B
1               2                3        4              5        6               7
300bp
Exon 51-Exon 52-Exon 53
Exon 51-int. acGFP-Exon 53 400bp
Exon 53
mini-gene RTM4        RTM2      RTM4  RTM1       RTM3
mini-gene mini-gene mini-gene mini-gene
3‘BD 5‘BD
Figure 5. Double RNA trans-splicing between RTM and COL17A1 mini-gene. (A)ACOL17A1 mini-gene expression plasmid was constructed by
cloning the endogenous gene region exon 51–intron 51–exon 52–intron 52–exon 53 of COL17A1 into a pcDNA 3.1D/V5-HIS expression vector
(Invitrogen). Co-transfection of the COL17A1 mini-gene expression plasmid and a functional RTM generated RNA trans-splicing between the
middle portion of acGFP carried by the RTM to exon 51 and 53 of the target molecule. (B) One day after HEK293AD cells were co-transfected with
either RTM 1 (lane 6), 2 (lane 4), 3 (lane 7), or 4 (lane 5) and COL17A1 target mini-gene expression plasmids, double trans-splicing was detected by
RT–PCR. Using a COL17A1 mini-gene speciﬁc primer pair (exon 51 COL17A1 speciﬁc forward primer, exon 53 COL17A1 speciﬁc reverse primer) it
is possible to discriminate between the product of cis-splicing (exon 51–exon 52–exon 53=442bp) or trans-splicing (exon 51—middle acGFP
fragment—exon 53=358bp). No trans-splicing products were detected by RT–PCR of RNA from HEK293AD cells transfected with COL17A1
mini-gene expression plasmid (lane 2) or RTM 4 (lane 3) alone. Lane 1: DNA ladder mix (Fermentas).
e108 Nucleic Acids Research, 2011,Vol.39, No. 16 PAGE 8 OF 11with RTM 2 and target expression plasmids were also
selected by FACS sorting with a purity of  90% (data
not shown). Removal of the untransfected cells increased
the intensity of the acGFP band signiﬁcantly (Figure 7,
lane 3).
DISCUSSION
In this study we demonstrate that IER is a technology that
has potential applications in treating genetic diseases.
However, at present there are no rules or guidelines for
designing highly efﬁcient double trans-splicing RTMs.
Building RTMs one at a time and testing them for efﬁ-
ciency is an arbitrary and arduous process. Thus we have
developed a rapid screening system to screen for efﬁcient
BDs to two introns ﬂanking a given exon. As a model
system we chose to replace exon 52 of the COL17A1
gene, a gene mutated in the devastating disease of the
skin and mucous membranes EB.
The methodology of RNA trans-splicing provides
many important advantages over conventional gene
Figure 6. Detection of acGFP expression by ﬂow cytometry. Flow cytometric analysis of HEK293AD cells co-transfected with one RTM and target
expression plasmids demonstrates the ability to discriminate between weak and highly efﬁcient RTMs. Single transfection of HEK293AD cells with
target molecule plasmid (A), RTM 2 (B) or RTM 4 (C) did not generate any expression of acGFP. Transfection of target molecule in combination
with RTM 0, which does not have a speciﬁc BD for intron 52, generates weak acGFP expression in  0.7% of analyzed cells (D). The RTMs 1 (E)
and 3 (F) generated acGFP expression in 4.2 and 12.8% of co-transfected cells. RTM 2 (G) and 4 (H) demonstrated the greatest trans-splicing
efﬁciency, up to 61% of co-transfected HEK293AD cells were green, and the geometric mean level of acGFP expression was signiﬁcant greater. All
RTMs harbor the same 30 BD speciﬁc for intron 51, but differ in the binding sequences complementary to intron 52 of COL17A1 (Figure 3).
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reprogrammed to wild-type, thus reducing the amount
of cis-spliced disease associated gene expression. RNA
trans-splicing can be used to replace 50,3 0 or internal
exon(s), referred to as 50,3 0 or IER. To date, several
groups have shown functional RNA repair using either
30 or 50 RNA trans-splicing in genetic diseases (6–12).
Still, there are many distinct genetic conditions in which
combining 30 and 50 trans-splicing might be advantageous
or even the only feasible therapeutic strategy. Such situ-
ations occur for example when the gene segment to be
replaced by 30 or 50 RNA trans-splicing is too large to be
delivered by existing vectors. IER permits the use of
RTMs, which are only  200nt larger than the exon(s)
to be replaced. Double trans-splicing RTMs do not need
to deliver the full-length coding sequence of a gene, un-
translated regions (UTRs) and start or termination
codons. Alternatively spliced exons and regulatory se-
quences within the 50- and 30-UTRs, which are essential
for mRNA stability and translation regulation, are left
intact in the target pre-mRNA. One such gene is PLEC,
which has multiple mRNA isoforms some that exceed
14kb. Mutations in this gene lead to a subgroup of EB
that is associated with progressive form of late onset
muscular dystrophy (EBS-MD). In this case, 30 or 50
RNA trans-splicing repair can only be applied to a
fraction of EB patients that carry mutations in exons
located at the 50- and 30-end of the gene. The terminal
exon of PLEC, exon 32, is >6.5kb by itself. Therefore,
double trans-splicing to replace the 3.38kb coding
sequence of exon 31, is required to effect delivery and
repair of mutations in this major EBS-MD disease
associated region. Additionally, the expression of PLEC
isoforms, should not be altered, except for the correction
of mutations within the targeted exon.
Other promising target genes for IER are the EB
associated genes COL17A1 and COL7A1. Both of these
genes have been corrected using 30 trans-splicing (6,18).
In vitro studies by Murauer et al. demonstrated a pheno-
typical correction of COL7A1 in dystrophic EB (DEB)
patient cells. Primary keratinocytes from a DEB patient
were transduced with a retrovirus encoding a 30 RTM
designed to repair COL7A1 exons 65–118. Signiﬁcant
levels of normal type VII collagen expression was
restored. The treated keratinocytes secreted type VII
collagen at the basement membrane zone in skin equiva-
lents. A double RNA trans-splicing strategy may be
needed to repair many of the internal exons (exons
upstream of exon 65) of COL7A1 as the 30 trans-splicing
strategy described above would require an RTM that
exceeds the packaging limit of many delivery systems.
A double trans-splicing RTM is a tool that can replace
one or more internal exons of a targeted pre-mRNA. The
exons to be reprogrammed by the RTM are chosen on the
basis of their clinical relevance. The design of the other
RTM elements is much more empiric. Alternative se-
quences for the spacers, 30 and 50 splice sites can
modulate trans-splicing efﬁciency or speciﬁcity; however,
the sequence of the BDs and their interactions with the
pre-mRNA target clearly has a profound effect (1–3). At
present the rules for building optimal double trans-splicing
RTMs are unknown. Therefore we created a ﬂuorescence
based screening system to rapidly identify the most efﬁ-
cient double trans-splicing RTMs from a library of RTMs
with target speciﬁc, but random position and length of
BDs.
In the ﬂuorescence based screening system, the repair of
the reporter molecule acGFP acts as marker for speciﬁc
double trans-splicing events in co-transfected cells. Using
ﬂow cytometry, we were able to rapidly evaluate and
compare the trans-splicing efﬁciency of RTMs differing
in their target binding sequences. Up to 60% of
analyzed HEK293AD cells expressed high levels of
acGFP after co-transfection with target and either
double trans-splicing RTM 2 or RTM 4. Under the
same co-transfection conditions, other RTMs with an
identical 30 BD but no or a different 50 BD generated
0.7–13% green cells. There are several possible explan-
ations for the observed difference in efﬁciency: (i) It is
likely that binding to the target molecule requires that
37kDa
25kDa
Annexin I (37kDa)
acGFP (27kDa)
acGFP RTM2 RTM3 RTM1RTM2 RTM4  RTM0 RTM2 RTM4 target
control target target target target target target
1            2                3        4        5       6       7         8        9       10      11
sorted
Figure 7. Detection of full-length acGFP restoration by western blot analysis. After co-transfection of target molecule and either RTM 2 (lane 6),
4 (lane 7), or 3 (lane 4), acGFP protein (27kDa) was detected by western blot analysis. As positive control, total-cell extract from acGFP control
vector (acGFP cloned in pcDNA 3.1D/V5-HIS vector, Invitrogen) transfected HEK293AD cells was also included (lane 2). Lane 3 demonstrates a
signiﬁcant increase ( 3-fold) in the amount of acGFP protein in acGFP positive cells collected by FACS sorting of HEK293AD cells co-transfected
with RTM 2 and target expression plasmids (lane 3) compared to total cell extract from co-transfected HEK293AD cells without sorting (lane 6). No
detectable acGFP expression was visible after single transfection of target molecule (lane 11), RTM 4 (lane 10) or RTM 2 (lane 9) into HEK293AD
cells. No expression of acGFP was detected by western blot analysis of HEK293AD cells co-transfected with target molecule and either RTM 1
(lane 5) or RTM 0 (which is missing a speciﬁc BD for intron 52, lane 8). Annexin I (37kDa) was included as the loading control for this experiment.
Lane 1: Precision Plus Protein WesternC Standards (Biorad).
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interact with itself or other molecules in the nucleus;
(ii) two discontinuous BDs may be more stable or more
difﬁcult to completely disrupt than a single BD; (iii) block-
age of the exon/intron boundary of the target molecule,
accomplished by the longer BD of RTM 2, may interfere
with recognition of the exon 52 50 splice site and facilitate
trans-splicing; and (iv) BDs with higher GC content may
be more stable in binding to the target region. The BDs of
RTM 2 (BD c=61% G+C, BD d=66%) and RTM 4
(BD f=57%, BD g=56%) have a higher GC content in
comparison to those of RTM 1 (47% G+C) and RTM 3
(52%). The essential point is that the BDs for both trans-
splicing reactions (30 and 50) must work together well for
efﬁcient trans-splicing replacement of the target exon.
Immunostaining was performed to conﬁrm the production
of full-length 27-kDa acGFP protein. Very low-level ex-
pression of acGFP was detected by ﬂow cytometric
analysis of HEK293AD cells co-transfected with target
molecule and RTM 0, which has no speciﬁc 50 BD. This
may have been caused by the RTM performing a speciﬁc
30 trans-splicing reaction into the target and a relatively
non-speciﬁc 50 trans-splicing reaction into the target,
facilitated by the interaction of the single BD of the
RTM with the target. We also created a trans-splicing
model system that more closely resembles the endogenous
gene. A COL17A1 target mini-gene was created with fully
endogenous sequence from exon 51 through exon 53, with
the intervening exon/intron boundaries. This model allows
for further characterization and selection of double trans-
splicing RTMs in a standard cell line (e.g. HEK293AD
cells) prior to ﬁnal selection in EB patient cells. Since
there are no general rules for predicting optimal binding
regions of a pre-mRNA of interest, the described RTM
screen represents a promising tool to optimize gene cor-
rection by spliceosome mediated RNA trans-splicing.
Different RTM-BDs and spacer region sequences can be
rapidly evaluated by this screen. This should reduce time
and effort required to select optimal RTMs prior to testing
them in the more complex, but highly relevant endogenous
gene expression model systems. In this report we have
demonstrated that 50 and 30 RNA trans-splicing can be
combined as a promising tool to repair large genes or
those that occur in multiple isoforms. Our ﬂuorescence
based RTM screening system should help to more
rapidly optimize RNA correction by trans-splicing to
higher levels, which should have a greater probability to
correct genetic diseases.
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